Biotechnology

Monday Sep 27, 2021 - 11:57 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation

WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infectionCybin is on a mission to revolutionize mental healthcare A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental…

Monday Sep 27, 2021 - 10:30 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space

Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patientsAnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the futureCompany’s proprietary CDA technology is powered by a database of over 220,000 clinical and general population test…

Friday Sep 24, 2021 - 6:01 am

Brain Scientific Inc. (BRSF) is Making EEGs Accessible to 5,900 US Hospitals

5,900 hospitals in the US lack the necessary extensive EEG techBRSF has created a cost-effective solution capable of supplying these hospitals with the equipment needed and broadening the reach of each neurologistEmergency departments and hospitals are not the only markets in need of brain monitoring devices, and the industry is expected to grow to $208 billion by 2023 For most U.S. patients, an EEG is…

Thursday Sep 23, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causesThe clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of MichiganTryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall…

Wednesday Sep 22, 2021 - 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screeningCompany’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased…

Tuesday Sep 21, 2021 - 2:20 pm

The Cannabis Society, European Medical Cannabis Conference To Showcase World Leaders For Discussions On The Growing World Cannabis Ecosystem

European Medical Cannabis Conference Tue, Sep 21 at 9:00 AM-5:00 PMHybrid Conference - Virtual and In-PersonPhysical Venue: Schützenstraße 73, 10117 Berlin, Germany MSO Growth and Consolidation Cannabis Conference Tue, Sep 21 at 9:00 AM-5:00 PMVirtual Conference only The European Medical Cannabis Conference and the MSO Growth and Consolidation Conference, organized by The Cannabis Society, invites medical professionals, professors, distributors, and experts for its hybrid physical/online…

Monday Sep 20, 2021 - 12:48 pm

RYAH Group Inc. (CSE: RYAH) Devices Ideal for Implementation of New Cannabis Intake Control Recommendations

Research team uses Delphi process for the first time to identify ideal cannabis dosing guidelines.After several rounds of voting, the ‘global task force’ created three separate dosing protocols.RYAH Group’s suite of precision dosing devices provide a practical way to safely execute these — or any — recommended dosing guidelines. Dosing recommendations are critical in any health treatments, but where cannabis is concerned, dosing levels have…

Friday Sep 17, 2021 - 9:15 am

Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetessugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDANemaura continues to build a world-class management teamNemaura plans to launch a direct to consumer…

Friday Sep 17, 2021 - 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc.BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoidsUpon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating companyAcquisition provides InMed with the complete flexibility across multiple manufacturing approaches On…

Friday Sep 17, 2021 - 9:00 am

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidateThe company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concernsTryp is preparing Phase 2a and Phase 2b clinical trials…

Wednesday Sep 15, 2021 - 1:39 pm

Potential for Psychedelic treatments Drives Mind Cure Health Inc.’s (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Strategy for Therapeutics Profitability

Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapiesPsychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are overcoming stigmas that arose from recreational use of the drugMind…

Monday Sep 13, 2021 - 2:06 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics spaceThe company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disordersTryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the…

Friday Sep 10, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview

Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug developmentOn the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled for full commercial launch in Q1 2022MCUR has successfully synthesized the…

Thursday Sep 09, 2021 - 11:22 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) programTryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases…

Wednesday Sep 08, 2021 - 9:30 am

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals ChinaA recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world…

Wednesday Sep 08, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needsThe company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapyTryp recently announced that its educational…

Friday Sep 03, 2021 - 11:07 am

Brain Scientific Inc. (BRSF) Addressing Immediate and Long-Term Needs of the Neurological Marketplace

The need for neurological services is increasing while the gap in access to care for patients is only increasingNeurological services are facing the challenge of a more contagious variant, staff shortage, and trying to uncover the reason for long-term symptoms in those who have had COVID Brain Scientific (OTCQB: BRSF), a commercial stage healthcare company, is bridging the widening gap in patient access to care.…

Wednesday Sep 01, 2021 - 9:59 am

With a Focus On AI and ML Technology, Brain Scientific Inc. (BRSF) Is Positioned to Take The Lead in Growing EEG Market

Brain Scientific focused on leveraging AI and ML to detect neurological diseases, aims to create comprehensive database of brain biomarkers to increase diagnosis accuracyBrain Scientific positioned to disrupt EEG market with FDA-cleared patented products that provide cost-effective brain imaging in any settingCurrent global EEG device market estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026…

Friday Aug 27, 2021 - 1:28 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposesThe prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelicsThe 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance…

Friday Aug 27, 2021 - 10:42 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucomaInMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plantsIn addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is…

Thursday Aug 26, 2021 - 10:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocolsAnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstreamAnPac Bio’s technology can be combined with the…

Wednesday Aug 25, 2021 - 10:25 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoidsInMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sourcesIntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scalesTo date, GW Pharma’s…

Monday Aug 23, 2021 - 10:43 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchangeCybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEOSeveral of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with…

Friday Aug 20, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research Mind Cure also continues…

Thursday Aug 19, 2021 - 10:36 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trialsCalvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall performTRP-8803 and TRP-8802 are psilocybin-based products being evaluated…

Thursday Aug 19, 2021 - 10:03 am

Brain Scientific Inc. (BRSF) Addresses Growing Epilepsy Problem With Portable Low-Cost Brain Monitoring Devices

CDC reports epilepsy is growing problem, 3.4 million people afflicted in the USAccording to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same periodBrain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year More Americans are suffering from epilepsy than…

Tuesday Aug 17, 2021 - 9:30 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatmentsResults come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research LibraryModel learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in the space where artificial intelligence and precision medicine intersect, Predictive Oncology (NASDAQ:…

Tuesday Aug 17, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Welcomes Digital Technology Expert in Development of Doctor-Patient SaaS Tech

Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology The company is focused on developing digital therapeutics technology and researching psychedelic compoundsThe company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization…

Tuesday Aug 17, 2021 - 9:00 am

Brain Scientific Inc.’s (BRSF) Technology Could Be Part of the Solution as New Research Finds that Neurological Consequences of COVID-19 Could be the Norm Rather than Exception

It has become known that COVID-19 patients can present with neurological symptoms, but new comprehensive cross-country study indicates that it could be more prevalent than previously thoughtThis could represent enormous challenge to healthcare as it needs to prepare for immediate and longer-term rehabilitation care of these patientsBrain Scientific is committed to remaining at forefront of brain diagnostics, potentially offering solution to higher need for neurological…

Tuesday Aug 17, 2021 - 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors

Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., LtdAnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devicesAnPac Bio’s board now includes Mr. Chao Feng who has global fortune 500 Companies’ managerial experience as independent director effective July…

Friday Aug 13, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast

Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industryDuring the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disordersGreg also shared the challenges that the industry is facing currently, mostly to do with legislationMcKee also shared how people can help the company and the industry…

Friday Aug 13, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Bolsters its Advisory Board With The Appointment of Jerry White

Mind Cure Health Inc. announced Jerry White’s appointment into the company’s advisory boardMr. White brings a wealth of experience from his years of powering global movements and working with key leaders and personalities around the worldMINDCURE forecasts that with Mr. White’s addition to the board, the company will be well-positioned to achieve bigger and better goals, all while working towards its overall vision of building…

Thursday Aug 12, 2021 - 11:33 am

Anpac Bio Continues Growth Trajectory

In recent years, advances in technology have led to demand for early cancer testing and screening methods that are less invasive and lower cost. Insurance companies have accepted that traditional testing methods are labor intensive and are not ideal as the first line of defense when screening and diagnosing cancer. This has opened a multi-billion-dollar market opportunity in discovering new solutions to tackle cancer and…

Tuesday Aug 10, 2021 - 11:05 am

Brain Scientific Inc. (BRSF) Addresses Critical Neurologist Shortfall with Cost-Effective, Portable Brain Diagnostic Devices

American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disordersBrain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any settingProduct development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditionsNeuroCap and NeuroEEG device patents approved in U.S., Europe and China With a goal of addressing the current acute…

Monday Aug 09, 2021 - 1:11 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise

InMed announced a non-binding letter of intent to acquire BayMedica Inc.The move is designed to grow InMed’s market presence and strengthen its operationsThe two companies have had a reciprocal research collaboration that dates back to November 2020InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028 InMed Pharmaceuticals (NASDAQ: INM) is a…

Monday Aug 09, 2021 - 12:09 pm

Brain Scientific Inc. (BRSF) Positioned to Disrupt EEG Market with Cost-Effective Brain Imaging Devices

Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any settingCurrent global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026 With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care…

Friday Aug 06, 2021 - 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screeningsThe global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of…

Friday Aug 06, 2021 - 9:00 am

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicineCannabis in sports medicine took center stage at the Tokyo OlympicsAmerican athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for…

Thursday Aug 05, 2021 - 1:22 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disordersThe initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needsPFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain…

Thursday Aug 05, 2021 - 12:05 pm

Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market

Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homesCurrent global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026 Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions